1.1 Introduction
Biotechnology is defined as the application of biological systems, living organisms, or their derivatives to develop or modify products and processes for specific use in human health and industry (International Centre for Genetic Engineering and Biotechnology, 2023). In the context of healthcare, biotechnology is widely used in vaccine development, drug formulation, and diagnostic innovation, where molecular and genetic techniques are applied to address complex diseases such as malaria. Malaria remains a major parasitic disease caused by Plasmodium species and transmitted through the bite of infected Anopheles mosquitoes, contributing significantly to global health burdens, particularly in Africa (World Health Organization, 2024). The introduction of biotechnology into malaria vaccine production has transformed traditional approaches to disease prevention by enabling the development of recombinant vaccines, antigen-based formulations, and genetically engineered parasite targets (Draper et al., 2018).
As a prelude to other parts of this study, this chapter will discuss the background upon which this study was initiated, the statement of problems that led to this study, the Aim and Objectives of the study. Others are significance of the study, scope of work, research hypothesis and questions, limitation of the study and definition of terms.
1.2 Background of Study
Malaria remains one of the most devastating infectious diseases globally, with the highest burden concentrated in sub-Saharan Africa, particularly Nigeria. According to World Health Organization, malaria continues to pose a significant public health challenge, accounting for hundreds of millions of cases annually and a substantial proportion of global malaria-related deaths. The disease is caused by parasites of the genus Plasmodium, transmitted through the bite of infected female Anopheles mosquitoes. Despite long-standing interventions such as insecticide-treated nets, indoor residual spraying, and antimalarial medications, transmission persists due to parasite resistance, mosquito adaptability, and weak health system structures (WHO, 2024).
According to Greenwood et al. (2019), malaria control efforts have historically focused on vector management and chemotherapy, but these approaches have not been sufficient to eliminate the disease in high-burden regions. The authors reported that the emergence of drug-resistant Plasmodium falciparum strains and insecticide-resistant mosquito vectors has significantly reduced the effectiveness of conventional control strategies. On the other hand, vaccine development has emerged as a promising complementary strategy aimed at reducing infection rates and interrupting transmission cycles (Greenwood et al., 2019).
Smith and Wilson (2020) asserted that, biotechnology is the application of genetic engineering, recombinant DNA technology, and cellular manipulation to develop products that improve human health outcomes. The authors affirmed that these technologies have transformed vaccine production by allowing scientists to identify specific parasite antigens and develop targeted immune responses. In malaria research, biotechnology has facilitated the identification of key antigens such as circumsporozoite proteins, which are critical in vaccine formulation. According to Draper et al. (2018), advances in biotechnology have led to the development of malaria vaccine candidates such as RTS,S/AS01 and R21/Matrix-M, which represent significant milestones in infectious disease prevention. The authors stated that these vaccines are based on recombinant protein technology that stimulates immune responses against the malaria parasite during its early liver stage.
In Africa, malaria continues to exert enormous social and economic burdens. According to WHO (2024), the continent accounts for over 90 percent of global malaria cases and deaths, with Nigeria contributing a significant proportion of this burden. The organization affirmed that weak healthcare infrastructure, limited access to advanced medical technologies, and inadequate local pharmaceutical production capacity continue to hinder effective malaria prevention and treatment.
In the Nigerian pharmaceutical industry, biotechnology adoption is gradually increasing, but it remains at a developmental stage. According to Okeke and Nnamdi (2021), Nigeria's pharmaceutical sector is heavily dependent on imported raw materials and finished products, which limits the country's ability to independently produce advanced biologics such as vaccines. The authors reported that insufficient investment in research and development, limited technical expertise, and inadequate infrastructure are major barriers to biotechnology advancement in the country. On the other hand, there is growing interest in strengthening local production capacity through public-private partnerships and policy reforms aimed at enhancing biotechnology integration. Furthermore, according to Ibe and Chukwu (2020), successful malaria vaccine production requires strong collaboration between research institutions, biotechnology firms, and pharmaceutical manufacturers. The authors contended that such collaboration is often weak in Nigeria, resulting in a disconnect between scientific innovation and industrial application.
This study is set against the backdrop of the need to evaluate the role of biotechnology in malaria vaccine production within Fidson Healthcare Plc and to understand the opportunities and constraints shaping its application in Nigeria's pharmaceutical sector.
1.3 Statement of Problems
Investigation revealed that malaria remains one of the most severe public health challenges in sub-Saharan Africa, particularly in Nigeria, where it contributes significantly to morbidity and mortality rates among children under five and pregnant women (World Health Organization, 2024). In recent years, biotechnology has emerged as a critical scientific approach in malaria vaccine production, offering innovative methods such as recombinant DNA technology, antigen engineering, and molecular biology techniques to enhance vaccine efficacy and scalability.
On the other hand, pharmaceutical manufacturing firms are positioned within the broader health biotechnology ecosystem, yet their involvement in advanced vaccine production remains limited due to infrastructural constraints, regulatory bottlenecks, and dependence on imported biotechnological inputs.
Furthermore, global progress in malaria vaccine development, including RTS,S/AS01 and R21/Matrix-M, demonstrates the feasibility of biotechnology-driven solutions, but highlights disparities in production access between developed and developing economies (Draper et al., 2018; WHO, 2024). It is against this backdrop that this study seeks to examine the role of biotechnology in malaria vaccine production, with a focus on Fidson Healthcare Plc.
1.4 Aim and Objectives of Study
The aim of the study is to assess the role of biotechnology in malaria vaccine production using Fidson Healthcare Plc as a case study. In achieving this aim, the following specific objectives were laid out as follows:
- To examine the level of biotechnology adoption in malaria vaccine production within Fidson Healthcare Plc.
- To identify the biotechnological methods used in malaria vaccine development.
- To evaluate the challenges affecting biotechnology application in malaria vaccine production.
- To assess the impact of biotechnology on vaccine production efficiency and effectiveness.
- To determine the relationship between biotechnology infrastructure and malaria vaccine output in pharmaceutical manufacturing.
1.5 Research Questions
The study came up with research questions so as to be able to ascertain the above stated objectives. The specific research questions for the study are stated below as follows:
- What is the level of biotechnology adoption in malaria vaccine production within Fidson Healthcare Plc?
- What biotechnological methods are used in malaria vaccine development?
- What challenges affect the application of biotechnology in malaria vaccine production?
- How does biotechnology influence vaccine production efficiency and effectiveness?
- What is the relationship between biotechnology infrastructure and malaria vaccine output in pharmaceutical manufacturing?
1.6 Research Hypotheses
In order to pursue the objective of this study, the following generalized statements have been designed to guide and aids in obtaining the result for the experiment to be conducted. For this work, the null hypothesis will be represented with H0 while the alternative hypothesis will be represented with hypothesis H1.
Hypothesis 1
- H0: Biotechnology adoption has no significant effect on malaria vaccine production in Fidson Healthcare Plc.
- H1: Biotechnology adoption has a significant effect on malaria vaccine production in Fidson Healthcare Plc.
Hypothesis 2
- H1: There is no significant relationship between biotechnological methods and vaccine development outcomes.
- H1: There is a significant relationship between biotechnological methods and vaccine development outcomes.
Hypothesis 3
- H0: Biotechnology infrastructure has no significant impact on malaria vaccine production efficiency.
- H1: Biotechnology infrastructure has a significant impact on malaria vaccine production efficiency.
1.7 Significance of Study
It is believed that at the completion of the study, the Federal Ministry of Health will use the findings to strengthen national biotechnology-driven vaccine production policies. Also, Fidson Healthcare Plc will improve its biotechnology integration strategies for enhanced malaria vaccine production capacity.
Furthermore, biotechnology researchers will benefit from improved knowledge on applied vaccine production methods in malaria control. In addition, the National Agency for Food and Drug Administration and Control will enhance regulatory frameworks guiding biotechnology-based pharmaceutical production.
Lastly, the general public will benefit from improved vaccine development outcomes that will reduce malaria prevalence.
1.8 Scope of Study
The study focuses on biotechnology applications in malaria vaccine production within Fidson Healthcare Plc in Lagos State, Nigeria, and does not extend to other pharmaceutical companies or other disease vaccines outside malaria research.
1.9 Limitations of the Study
During the course of this study, there were some problems encountered which stood as limitations to the research work. Some of the limitations include:
- Time Constraint: The time frame given to accomplish this project was very short due to school academic calendar and it was carried out under pressure which made the researcher not to implement some necessary features.
- Financial Constraint: Insufficient fund tends to impede the efficiency of the researcher in sourcing for the relevant materials, literature or information and in the process of data collection (internet, questionnaire and interview).
- Initial Cooperation Delay from Respondents: A particular limitation of this work came as a result of the respondent refusal to offer their cooperation at the initial time they were contacted. This contributed in making the success of this research study difficult.
1.10 Definition of Terms
Biotechnology:
Biotechnology is defined as the application of living organisms, biological systems, or their derivatives to develop useful products, especially in medicine and healthcare (International Centre for Genetic Engineering and Biotechnology, 2023). It involves techniques such as genetic engineering and recombinant DNA technology used in vaccine development.
Malaria:
Malaria is a life-threatening disease caused byPlasmodiumparasites transmitted through infected femaleAnophelesmosquitoes, affecting millions globally, especially in Africa (World Health Organization, 2024).
Vaccine:
A vaccine is a biological preparation that stimulates the immune system to recognize and fight specific pathogens, thereby providing immunity against infectious diseases (Plotkin, 2018).
Recombinant DNA Technology:
Recombinant DNA technology is a genetic engineering method used to combine DNA molecules from different sources to produce new genetic combinations for medical and pharmaceutical applications (Smith & Wilson, 2020).
…